Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Prothena Corporation PLC (NASDAQ:PRTA)

65.97
Delayed Data
As of Jul 31
 -0.73 / -1.09%
Today’s Change
16.71
Today|||52-Week Range
69.88
+217.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.1B

Company Description

Prothena Corp. Plc is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. It also focuses on therapeutic monoclonal antibodies directed specifically to disease causing proteins. The company's antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis, Parkinson's disease and other related synucleinopathies and novel cell adhesion targets involved in inflammatory diseases and cancers. Prothena was founded on December 20, 2012 and is headquartered in Dublin, Ireland.

Contact Information

Prothena Corp. Plc
Alexandra House
Dublin Dublin 4
P:(531) 902-3519
Investor Relations:
(650) 837-8535

Employees

Shareholders

Mutual fund holders64.26%
Other institutional20.20%
Individual stakeholders10.25%

Top Executives

Dale B. SchenkPresident, Chief Executive Officer & Director
Tran B. NguyenChief Financial Officer & Head-Investor Relations
Gene G. KinneyChief Scientific Officer
Martin KollerChief Medical Officer
Tara NickersonChief Business Officer